$CIHN The trial will focus on providing therapies to limited option patients. Data collected will be compared against a control segment of standard, non-treated patients. Additionally, outcomes and safety data from Arm 2 patients will be compared against Arm 1 to establish differentials in therapy modalities.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.